肾上腺素给药间隔与儿科院内心脏骤停结局相关:一项多中心研究
该研究为ICU-RESUScitation项目(NCT028374497)的二次分析,纳入美国18个PICU和儿童心脏ICU中37周校正胎龄及以上、≤18岁、发生索引心脏骤停且接受至少2剂肾上腺素的382例患儿。主要暴露为肾上腺素给药间隔<3分钟 vs ≥3分钟,主要结局为出院存活且神经功能良好(PCPC评分1-2分或较基线无变化)。校正混杂因素后,间隔<3分钟与神经功能良好存活无关(aRR 1.10;95%CI 0.84-1.46;p=0.48),但与持续ROSC改善(aRR 1.21;95%CI 1.07-1.37;p<0.01)和CPR时长缩短(校正效应估计-9.5分钟;95%CI -14.4至-4.84分钟;p<0.01)相关。
要点
- 在382例接受至少2剂肾上腺素的儿科院内心脏骤停患儿中,给药间隔<3分钟与神经功能良好存活无关(aRR 1.10;95%CI 0.84-1.46;p=0.48)。
- 给药间隔<3分钟与持续ROSC改善相关(aRR 1.21;95%CI 1.07-1.37;p<0.01)。
- 给药间隔<3分钟与CPR时长缩短相关(校正效应估计-9.5分钟;95%CI -14.4至-4.84分钟;p<0.01)。
- 研究排除接受少于2剂肾上腺素、接受体外CPR或给药间隔>8分钟的患者。
适用人群与场景
- 纳入:≤18岁、校正胎龄≥37周、发生索引心脏骤停、接受至少2剂肾上腺素的患儿。
- 排除:接受少于2剂肾上腺素、接受体外CPR、给药间隔>8分钟的患者。
- 场景:美国18个PICU和儿童心脏ICU。
研究设计与关键结果
- 研究类型:多中心试验的二次分析;样本量382例;18个PICU和儿童心脏ICU;中位年龄0.9岁(IQR 0.3-7.6岁),45%为女性。
- 主要暴露:肾上腺素给药间隔<3分钟 vs ≥3分钟。
- 主要结局:出院存活且神经功能良好(PCPC评分1-2分或较基线无变化);校正后aRR 1.10(95%CI 0.84-1.46;p=0.48)。
- 关键次要结局:持续ROSC改善(aRR 1.21;95%CI 1.07-1.37;p<0.01);CPR时长缩短(校正效应估计-9.5分钟;95%CI -14.4至-4.84分钟;p<0.01)。
证据类型、等级与局限
- 证据类型:多中心试验的二次分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在接受至少2剂肾上腺素的儿科院内心脏骤停患者中,给药间隔<3分钟与神经功能结局无关,但与持续ROSC和更短CPR时长相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Data to support epinephrine dosing intervals during cardiopulmonary resuscitation (CPR) are conflicting. The objective of this study was to evaluate the association between epinephrine dosing intervals and outcomes. We hypothesized that dosing intervals less than 3 minutes would be associated with improved neurologic survival compared with greater than or equal to 3 minutes.
DESIGN: This study is a secondary analysis of The ICU-RESUScitation Project (NCT028374497), a multicenter trial of a quality improvement bundle of physiology-directed CPR training and post-cardiac arrest debriefing.
SETTING: Eighteen PICUs and pediatric cardiac ICUs in the United States.
PATIENTS: Subjects were 18 years young or younger and 37 weeks old or older corrected gestational age who had an index cardiac arrest. Patients who received less than two doses of epinephrine, received extracorporeal CPR, or had dosing intervals greater than 8 minutes were excluded.
INTERVENTIONS: The primary exposure was an epinephrine dosing interval of less than 3 vs. greater than or equal to 3 minutes.
MEASUREMENTS AND MAIN RESULTS: The primary outcome was survival to discharge with a favorable neurologic outcome defined as a Pediatric Cerebral Performance Category score of 1-2 or no change from baseline. Regression models evaluated the association between dosing intervals and: 1) survival outcomes and 2) CPR duration. Among 382 patients meeting inclusion and exclusion criteria, median age was 0.9 years (interquartile range 0.3-7.6 yr) and 45% were female. After adjustment for confounders, dosing intervals less than 3 minutes were not associated with survival with favorable neurologic outcome (adjusted relative risk [aRR], 1.10; 95% CI, 0.84-1.46; p = 0.48) but were associated with improved sustained return of spontaneous circulation (ROSC) (aRR, 1.21; 95% CI, 1.07-1.37; p < 0.01) and shorter CPR duration (adjusted effect estimate, -9.5 min; 95% CI, -14.4 to -4.84 min; p < 0.01).
CONCLUSIONS: In patients receiving at least two doses of epinephrine, dosing intervals less than 3 minutes were not associated with neurologic outcome but were associated with sustained ROSC and shorter CPR duration.
参考来源
- Kienzle MF, Morgan RW, Reeder RW, et al. Epinephrine Dosing Intervals Are Associated With Pediatric In-Hospital Cardiac Arrest Outcomes: A Multicenter Study. Crit Care Med. 2024. PMID: 38833560. doi:10.1097/CCM.0000000000006334
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。